Urvi Patel, PA
Physician Assistant · Greenbelt, MDNPI 1265656185
Payments from drug & device makers
Across 277 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$976
- Novo Nordisk$819
- Corcept Therapeutics$568
- Cequr Corporation$439
- Sanofi-aventis U.S. LLC$431
- Xeris Pharmaceuticals, Inc.$369
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,195100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 51 | $976 |
| Novo Nordisk | 40 | $819 |
| Corcept Therapeutics | 24 | $568 |
| Cequr Corporation | 3 | $439 |
| Sanofi-aventis U.S. LLC | 17 | $431 |
| Xeris Pharmaceuticals, Inc. | 19 | $369 |
| Radius Health, Inc. | 15 | $295 |
| Insulet Corporation | 12 | $259 |
| Amneal Pharmaceuticals LLC | 10 | $218 |
| Tandem Diabetes Care, Inc. | 8 | $174 |
| Amgen | 8 | $146 |
| AbbVie | 6 | $138 |
| Recordati_rare_diseases_inc. | 7 | $131 |
| Amphastar Pharmaceuticals, Inc. | 6 | $122 |
| AstraZeneca(2 entities) | 5 | $120 |
| Bayer | 4 | $107 |
| Antares Pharma, Inc. | 4 | $99 |
| Madrigal Pharmaceuticals | 5 | $90 |
| Medtronic | 3 | $89 |
| Boehringer Ingelheim | 4 | $86 |
| Tolmar, Inc. | 4 | $81 |
| Arcutis Biotherapeutics, Inc. | 4 | $64 |
| Abbott | 3 | $57 |
| Acella Pharmaceuticals, LLC | 3 | $50 |
| Dexcom, Inc. | 2 | $48 |
| Astellas Pharma US Inc | 2 | $47 |
| Halozyme Inc | 2 | $42 |
| Boston Scientific | 1 | $28 |
| Embecta Corp. | 1 | $27 |
| BETA Bionics, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$340
How this compares
$6,206 in reported general payments places this provider in the 95th percentile of 2,567 physician assistant providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 232 | $475,729 |
| OzempicSemaglutide | 196 | $399,475 |
| TrulicityDulaglutide | 161 | $301,703 |
| JardianceEmpagliflozin | 186 | $250,634 |
| Tresiba Flextouch U-200Insulin Degludec | 115 | $198,696 |
| Tresiba Flextouch U-100Insulin Degludec | 85 | $72,707 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 105 | $68,227 |
| JanuviaSitagliptin Phosphate | 35 | $45,253 |
| FarxigaDapagliflozin Propanediol | 33 | $44,167 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $32,590 |
| TradjentaLinagliptin | 22 | $25,310 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $24,959 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $16,524 |
| Humalog Kwikpen U-100Insulin Lispro | 57 | $16,082 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 179 | $15,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $976 | $777,432393 claims |
| Novo NordiskOzempic | $819 | $399,475196 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $86 | $289,328219 claims |
| AstraZenecaFarxiga | $120 | $44,16733 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $218 | $3,196224 claims |
| AbbVieSynthroid | $138 | $2,97138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,567 physician assistant providers in Maryland.
Other physician assistant in Greenbelt
- Allison ScadutoGreenbelt$13K
- Lynn AllisonGreenbelt$12K
- Helen ChemereGreenbelt$11K
- Margaret JoyceTowson$220K
- Kara CossisBaltimore$177K
- Michael RitmillerOwings Mills$92K
- Garland JamesSilver Spring$86K
- Melissa BearekmanBaltimore$81K
- Brittany YerkesSalisbury$81K
- Bruce SmithBaltimore$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.